Compare GRNQ & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRNQ | PLUR |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | Malaysia | Israel |
| Employees | 41 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 12.5M |
| IPO Year | 2014 | 2026 |
| Metric | GRNQ | PLUR |
|---|---|---|
| Price | $7.10 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 53.8K | ★ 59.5K |
| Earning Date | 11-20-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,673,997.00 | $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.55 | N/A |
| 52 Week Low | $1.12 | $0.85 |
| 52 Week High | $318.00 | $4.87 |
| Indicator | GRNQ | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 56.56 |
| Support Level | $6.34 | $0.88 |
| Resistance Level | $12.05 | $1.43 |
| Average True Range (ATR) | 0.63 | 0.15 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 61.81 | 59.26 |
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.